【行业观察】 集采七年 降药价更促创新
Zheng Quan Shi Bao·2025-10-30 19:09

Core Insights - The eleventh batch of national drug procurement results was announced, with 445 companies and 794 products participating, and 272 companies with 453 products winning the proposed selection [1] - Drug procurement has evolved from a groundbreaking reform into a normalized and institutionalized industry rule, significantly impacting the domestic pharmaceutical industry [1][2] - The focus of drug procurement has shifted from price competition to value competition, indicating a mature new trend in the industry [1][2] Group 1: Price Reduction and Quality Control - Price reduction remains a key focus of drug procurement, aiming to eliminate excess costs and provide patients with high-quality, affordable medications [1][2] - The eleventh batch introduced an innovative price control mechanism that prevents excessive competition by switching the price anchor when the lowest bid is below 50% of the average bid [1][2] - Quality control has become a critical aspect, with higher quality thresholds for bidding, requiring companies to have no quality violations in the past two years [2] Group 2: Innovation and Industry Upgrade - Drug procurement not only emphasizes price reduction but also encourages innovation, pushing the industry away from reliance on generic drugs [2][3] - The focus on mature products that have passed patent expiration is intended to stimulate companies to invest in innovative drug development [2][3] - The Chinese capital market is increasingly focused on innovative drugs, with the number of applications ranking second globally, supported by policies aimed at fostering innovation in the pharmaceutical sector [3] Group 3: Sustainable Development and Future Outlook - The ongoing drug procurement process is reshaping not only drug prices but also the industry ecosystem and development logic, promoting healthier and more sustainable growth [3] - The expectation is for drug procurement to work in synergy with other industrial policies to create a win-win ecosystem for patients, doctors, and companies [3]